Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493462 | 0.76 | PNMT (0.46) | MAOBPNMTCD44ALOX15HSD17B10 | |
| SCHEMBL4505442 | 0.76 | HTR2C (0.52) | MAOBPNMTCD44GAAMAOA | |
| Hydrochloric Acid SCHEMBL11863712 | 0.75 | HTR2C (0.50) | MAOBPNMTCD44GAANPSR1 | |
| Hydrochloric Acid SCHEMBL11691031 | 0.75 | PNMT (0.45) | MAOBPNMTCD44ALOX15HSD17B10 | |
| SCHEMBL16661726 | 0.72 | TIPARP (0.36) | ALOX15HSD17B10 | |
| SCHEMBL16365948 | 0.72 | TIPARP (0.33) | — | |
| SCHEMBL13975659 | 0.72 | CHRNB2 (0.42) | — | |
| SCHEMBL3663958 | 0.70 | PNMT (0.50) | MAOBPNMTCD44ALOX15HSD17B10 | |
| SCHEMBL28034015 | 0.69 | ALOX15 (0.45) | MAOBPNMTCD44ALOX15HSD17B10 | |
| SCHEMBL4512915 | 0.67 | RYR2 (0.48) | OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003028739-A2 | COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA OR HYPERGLYCEMIA COMPRISING A POLYMER OR ITS SALT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | claimed |
| US-12509417-B2 | Enantioselective process | SYNGENTA CROP PROTECTION AG (CH) | 2025-12-30 | — | — | US | disclosed |
| CN-118453896-A | Antibody-drug conjugates, pharmaceutical compositions and therapeutic uses | 上海偌妥生物科技有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-113195460-B | Enantioselective process | 先正达农作物保护股份公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3877372-B1 | ENANTIOSELECTIVE REDUCTION OF OXIME-DERIVATIVES INVOLVING IRIDIUM BASED CATALYSTS | SYNGENTA CROP PROTECTION AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-20220106263-A1 | ENANTIOSELECTIVE PROCESS | SYNGENTA CROP PROTECTION AG (CH) | 2022-04-07 | — | — | US | disclosed |
| EP-3877372-A1 | ENANTIOSELECTIVE PROCESS | Syngenta Crop Protection AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| CN-113195460-A | Enantioselective process | 先正达农作物保护股份公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-109562944-A | hard mask composition | 亚历克斯·菲利普·格雷厄姆·罗宾逊 | 2019-04-02 | — | — | CN | disclosed |
| EP-2980136-B1 | PREPREG, FIBER-REINFORCED COMPOSITE MATERIAL, AND RESIN COMPOSITION CONTAINING PARTICLES | JXTG NIPPON OIL & ENERGY CORP (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| WO-2003028739-A2 | COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA OR HYPERGLYCEMIA COMPRISING A POLYMER OR ITS SALT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| WO-2002032974-A2 | POLYMER AND ITS USE FOR THE TREATMENT AND/OR PREVENTION OF HYPERPHOSPHOREMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-25 | — | — | WO | disclosed |
| US-6319916-B1 | CHOLINESTERASE INHIBITOR FOR SENILE DEMENTIA AND ALZHEIMER'S TREATMENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-0273399-B1 | Optically active 2,3-dihydrobenzoaxine derivatives and process for preparing the same | DAIICHI SEIYAKU CO (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0567090-A2 | Benzoxazepine derivatives as cholinesterase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0273399-A1 | Optically active 2,3-dihydrobenzoaxine derivatives and process for preparing the same | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509417-B2 | Enantioselective process | HCCS, AOC3, CYP8B1 | MAOB 278/4885PNMT 68/4885CD44 4212/4885 |
| US-20220106263-A1 | ENANTIOSELECTIVE PROCESS | CYP11B2, CYP2E1, CYP2F1 | MAOB 130/4885PNMT 304/4885CD44 3533/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | MAOB 259/4885PNMT 153/4885CD44 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.